Drug intelligence / Profile preview

Vicks Sinex Severe Cold & Flu

Development stage
Unknown
Lead developer
Procter & Gamble
Modality
Small Molecules
Administration
Intranasal
01

Overview

Vicks Sinex Severe Cold & Flu is an over-the-counter (OTC) multi-symptom medication developed by Vicks (a brand of Procter & Gamble) to alleviate symptoms associated with the common cold, influenza, and sinusitis. The formulation is typically delivered as oral LiquiCaps and contains a combination of active ingredients: acetaminophen, dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride. Acetaminophen acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Dextromethorphan hydrobromide is an antitussive that suppresses the cough reflex by acting on the cough center in the medulla. Guaifenesin is an expectorant that reduces the viscosity of respiratory secretions, making coughs more productive. Phenylephrine hydrochloride is a nasal decongestant that stimulates alpha-1 adrenergic receptors, causing vasoconstriction in the nasal mucosa to reduce swelling and congestion.

Brand names
SinexVicks SinexSinex SevereSinex Severe All-In-One
Other names
Sinex-Vicks-cold-flu-cough-sinus symptom relief
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)ADRA1A (α1A)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Vicks Sinex Severe Cold & Flu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vicks Sinex Severe Cold & Flu.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call